About Tandem Diabetes
Tandem Diabetes is a company based in San Diego (United States) founded in 2008.. Tandem Diabetes has raised $100.73 million across 6 funding rounds from investors including CRG. The company has 2,650 employees as of December 31, 2024. Tandem Diabetes has completed 4 acquisitions, including Advanced Microfluidics, Amf Medica and Capillary Biomedical. Tandem Diabetes operates in a competitive market with competitors including Kaleido, Modular Medical, LenoMed, Asante Solutions and Sooil Development, among others.
- Headquarter San Diego, United States
- Employees 2650 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Tandem Diabetes Care, Inc.
-
Annual Revenue
$940.2 M25.74as on Dec 31, 2024
-
Net Profit
$-96.03 M56.86as on Dec 31, 2024
-
EBITDA
$-82.52 M40.53as on Dec 31, 2024
-
Total Equity Funding
$100.73 M (USD)
in 6 rounds
-
Latest Funding Round
$287.5 M (USD), Post-IPO
May 15, 2020
- Investors
-
Employee Count
2650
as on Dec 31, 2024
-
Investments & Acquisitions
Advanced Microfluidics
& 3 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Tandem Diabetes
Tandem Diabetes is a publicly listed company on the NASDAQ with ticker symbol TNDM in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Unlock access to complete
Unlock access to complete
Software Development Team
79 people
Sales and Marketing
32 people
Leadership Team
31 people
Finance and Accounting
14 people
Human Resources and Administration
14 people
Operations Team
13 people
Senior Team
13 people
Product Management Team
11 people
Unlock access to complete
Funding Insights of Tandem Diabetes
Tandem Diabetes has successfully raised a total of $100.73M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $287.5 million completed in May 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Post-IPO — $287.5M
-
First Round
First Round
(07 Jan 2010)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2020 | Amount | Post-IPO - Tandem Diabetes | Valuation |
investors |
|
| Jan, 2018 | Amount | Post-IPO - Tandem Diabetes | Valuation |
investors |
|
| Jan, 2016 | Amount | Debt – Conventional - Tandem Diabetes | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Tandem Diabetes
Tandem Diabetes has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include CRG. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
CRG is recognized as a premier healthcare investment partner.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Tandem Diabetes
Tandem Diabetes has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include Advanced Microfluidics, Amf Medica and Capillary Biomedical. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Smart solutions for blood glucose monitoring are provided by Sugarmate.
|
2016 | ||||
|
Syringe pumps, electric rotary valves, and microfluidics are manufactured.
|
2014 | ||||
|
Minimally invasive implants for continuous glucose monitoring are provided.
|
2014 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Tandem Diabetes
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Tandem Diabetes Comparisons
Competitors of Tandem Diabetes
Tandem Diabetes operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Kaleido, Modular Medical, LenoMed, Asante Solutions and Sooil Development, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Insulin pumps and monitoring software for diabetes are developed.
|
|
| domain | founded_year | HQ Location |
Insulin pumps are developed for continuous delivery to diabetic patients.
|
|
| domain | founded_year | HQ Location |
Developer of closed loop insulin delivery devices
|
|
| domain | founded_year | HQ Location |
Insulin pump systems are developed and customized by Asante Solutions.
|
|
| domain | founded_year | HQ Location |
Develops insulin pumps and apps for diabetes care and blood sugar monitoring.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Tandem Diabetes
Frequently Asked Questions about Tandem Diabetes
When was Tandem Diabetes founded?
Tandem Diabetes was founded in 2008 and raised its 1st funding round 2 years after it was founded.
Where is Tandem Diabetes located?
Tandem Diabetes is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Is Tandem Diabetes a funded company?
Tandem Diabetes is a funded company, having raised a total of $100.73M across 6 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $80M, raised on Jan 07, 2010.
How many employees does Tandem Diabetes have?
As of Dec 31, 2024, the latest employee count at Tandem Diabetes is 2,650.
What is the annual revenue of Tandem Diabetes?
Annual revenue of Tandem Diabetes is $940.2M as on Dec 31, 2024.
What does Tandem Diabetes do?
Tandem Diabetes is a developer of devices for continuous glucose monitoring and manual insulin delivery. It develops insulin pumps other products and services that bring innovation, convenience style to diabetes management. The first product, the t: slim Insulin Pump, features a sleek, modern design, intuitive touch-screen interface, and a rechargeable lithium-polymer battery. The company claims that this makes them closer to producing a fully automated closed-loop automated insulin delivery device that will not require human intervention to release insulin.
Who are the top competitors of Tandem Diabetes?
Tandem Diabetes's top competitors include Kaleido, Modular Medical and LenoMed.
Is Tandem Diabetes publicly traded?
Yes, Tandem Diabetes is publicly traded on NASDAQ under the ticker symbol TNDM.
How many acquisitions has Tandem Diabetes made?
Tandem Diabetes has made 4 acquisitions, including Advanced Microfluidics, Amf Medica, and Capillary Biomedical.
Who are Tandem Diabetes's investors?
Tandem Diabetes has 1 investor. Key investors include CRG.
What is Tandem Diabetes's ticker symbol?
The ticker symbol of Tandem Diabetes is TNDM on NASDAQ.